RecruitingNCT02863757

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

Disease Progression and Clinical Outcomes in Chronic Hepatitis B (CHB) Patients With Comorbid Nonalcoholic Fatty Liver Disease (NAFLD)

Sponsor

Humanity and Health Research Centre

Enrollment

1,500 participants

Start Date

Aug 1, 2016

Study Type

OBSERVATIONAL

Conditions

Chronic Hepatitis B Nonalcoholic Fatty Liver Disease

Summary

The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with chronic hepatitis b and nonalcoholic fatty liver disease. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Humanity and Health GI and Liver Centre

Hong Kong, Hong Kong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02863757

Related Trials

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

NCT070695691 location

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT070933463 locations

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

NCT071461002 locations

A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B

NCT07635186

A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

NCT076007885 locations